{"id":"W3025905658","doi":"10.1016/j.clcc.2020.04.008","title":"Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)","year":2020,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Institute of Cancer Research; Bayer HealthCare; Institut National Du Cancer; Institut Bergonié; Direction Générale de l’offre de Soins; Institut National de la Santé et de la Recherche Médicale","keywords":"Medicine; Irinotecan; Internal medicine; Bevacizumab; Oxaliplatin; Colorectal cancer; Sorafenib; Clinical endpoint; Progression-free survival; Gastroenterology; Oncology; Phases of clinical research; Randomized controlled trial; Cancer; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001213186,0.00179239,0.002357511,0.0004589118,0.0003269167,0.001085894,0.0006064279,0.0009376625,0.004208792],"category_scores_gemma":[0.0008159295,0.0006448378,0.001598703,0.0004518254,0.0008998725,0.001300512,0.0003860455,0.002770025,0.0007492604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007595927,"about_ca_system_score_gemma":0.001035865,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001024355,"about_ca_topic_score_gemma":0.00320606,"domain_scores_codex":[0.9996579,0.0001572397,0.00001706381,0.00007500612,0.00002582957,0.0000669666],"domain_scores_gemma":[0.9996186,0.00006177341,0.00008312504,0.00002845361,0.00001989799,0.0001880634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9353368,0.008924377,0.001909726,0.0007085467,0.001733366,0.00008650663,0.0001065274,0.001321035,0.006961831,0.0002181896,0.002089465,0.04060367],"study_design_scores_gemma":[0.8960053,0.09716184,0.003518034,0.00003019226,0.0005907,0.00009288749,0.00004911623,0.0007422878,0.0006341307,0.0001651273,0.0009874252,0.00002287291],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928793,0.002992224,0.0003179417,0.0005750922,0.0002840327,0.0008457634,0.0005856449,0.00008576565,0.001434199],"genre_scores_gemma":[0.9886978,0.002946015,0.001239593,0.0007666641,0.000340089,0.001137725,0.001461934,0.00002920667,0.003381133],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004208792,"threshold_uncertainty_score":0.01407987,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04469850566048605,"score_gpt":0.3826672767687627,"score_spread":0.3379687711082766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}